Institution: | aNeuroscience Discovery, Abbott GmbH & Co. KG, D-67008 Ludwigshafen, Germany bAdvanced Technologies, Abbott Laboratories, Abbott Park, IL 60064-6101, USA cBASF AG, D-67056 Ludwigshafen, Germany |
Abstract: | Novel 5-HT1 autoreceptor ligands based on the N-4-aryl-piperazinyl-N′-ethyl-5,6,7,8-tetrahydropyrido4′, 3′:4,5]thieno2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a novel mode of action our objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT1A and 5-HT1B receptors. Strategies for the development of dual 5-HT1A and 5-HT1B antagonists based on 1 and 2 as leads and the corresponding results are discussed. Isoquinoline analogue 33 displayed high affinity and an antagonistic mode of action for the 5-HT1A and the 5-HT1B receptors and was characterized further with respect to selectivity, electrically stimulated 3H]5-HT release and in vivo efficacy. |